KaydedilenlerDerginizi ekleyin

Dergiler / Organic Communications / 2022 / Cilt: 15 - Sayı: 1

Comprehensive review on repurposing of approved medicine in the management of COVID-19 infection

Darshini PATEL
Umang SHAH
Arya PATEL
Sandip PATEL
Mehul PATEL
Ashish PATAL
Swayamprakash PATEL
Nilay SOLANKİ
Nilesh PANDEY
Sayfa
1–31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The purpose of this article is to evaluate and explore the potential roles of several medications now utilized in COVID-19.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:: The SARS-CoV-2 virus, accountable for the COVID-19 pandemic, is now sweeping the globe.
📊
Temel Bulgular & Veri:However, numerous medications have been studied for their efficacy and safety in treatment of COVID-19, with the majority currently undergoing clinical trials.
💡
Sonuç & Katkı:The purpose of this article is to evaluate and explore the potential roles of several medications now utilized in COVID-19.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

: The SARS-CoV-2 virus, accountable for the COVID-19 pandemic, is now sweeping the globe. As a result, as this disease resists testing and adoption of new treatments, repositioning existing medications may provide a quick and appealing method with established safety, features, and dose used. They are not, however, specific or focused. However, numerous medications have been studied for their efficacy and safety in treatment of COVID-19, with the majority currently undergoing clinical trials. The goal is to rapidly expand novel preventative and therapeutic medications, as well as to apply preventive methods such as early patient identification, isolation, and treatment. Moreover, reducing transmission through physical contact is also important. In the fight against this dangerous disease, finding the proper treatment is crucial. This article summarizes several anti-malarial, anti-parasitic, monoclonal antibodies, immunosuppressant, and immunomodulating agents in clinical trials for COVID-19. The purpose of this article is to evaluate and explore the potential roles of several medications now utilized in COVID-19.

🔖

Bu Makaleye Atıf Yap

PATEL, D., SHAH, U., PATEL, A., PATEL, S., PATEL, M., PATAL, A., PATEL, S., SOLANKİ, N., PANDEY, N. (2022). Comprehensive review on repurposing of approved medicine in the management of COVID-19 infection. Organic Communications, Cilt: 15 - Sayı: 1, 1–31. https://ajindex.com/articles/419566

Kaynakça (12)

  1. Ahmed, S. S. The Coronavirus Disease 2019 (COVID-19): A Review. J. Adv. Med. Med. Res., 2020, 32 (4), 1–9
  2. WHO, 2020. Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It. Geneva, Switzerland: World Health Organization
  3. Groot, J.D.; Baker, S.C.; Baric, R.S.; Brown, C.S.; Drosten, C.; Enjuanes, L.; Fouchier, R.A.M.; Galiano, M.; Gorbalenya, A.E.; Memish; Z.A.; et.al. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J. Virol. 2013, 87 (14), 7790–7792
  4. Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann. Intern. Med. 2020, 172 (9), 577–582
  5. Backer, J. A.; Klinkenberg, D.; Wallinga, J. Incubation period of 2019 novel coronavirus (2019-ncov) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. Bull. Eur. sur les Mal. Transm. = Eur. Commun. Dis. Bull. 2020, 25 (5)
  6. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X. et.al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395 (10223), 497–506
  7. Gupta, A.; Madhavan, M. V; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T. S.; Bikdeli, B.; Ahluwalia, N.; Ausiello, J. C.; Wan, E. Y. et.al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020, 26 (7), 1017–1032
  8. Carfì, A.; Bernabei, R.; Landi, F. Persistent symptoms in patients after acute COVID-19. JAMA, 2020, 324 (6), 603–605
  9. Tenforde, M. W.; Kim, S. S.; Lindsell, C. J.; Billig Rose, E.; Shapiro, N. I.; Files, D. C.; Gibbs, K. W.; Erickson, H. L.; Steingrub, J. S.; Smithline, H. A.; et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020, 69 (30), 993–998
  10. Huang, C.; Huang, L.; Wang, Y.; Li, X.; Ren, L.; Gu, X.; Kang, L.; Guo, L.; Liu, M.; Zhou, X.; et al
  11. Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021, 397 (10270), 220–232
  12. Chan, J. F.-W.; Kok, K.-H.; Zhu, Z.; Chu, H.; To, K. K.-W.; Yuan, S.; Yuen, K.-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypica